Unlearn.AI: Digital Twin Control Arms That Shrink Trials Without Weakening the Evidence

Overview: How Unlearn.AI’s AI‑Driven Digital Twin & Virtual Control Arm Platform Transforms Clinical Trial Design and Optimization

Unlearn.AI is an AI-driven clinical trial optimization platform that uses patient-level digital twins and virtual control arms to support trial design, protocol optimization, and operational scenario testing. Within the Clinical Trial Optimization Agents, Digital Twin & Virtual Control Arm Agents, and Protocol Design & Operational Scenario Testing category, it focuses on a core bottleneck in clinical development: the need to run large, time-consuming trials and make high-stakes design decisions based on fragmented evidence and limited upfront insight into how different design choices will affect outcomes.

At a high level, Unlearn.AI trains disease-specific machine learning models on extensive historical clinical trial and patient-level data to generate digital twins—AI-based forecasts of how individual participants would progress under standard of care—and uses these forecasts to simulate virtual control arms and compare protocol scenarios before and during a study. This enables teams to explore multiple endpoint, eligibility, and sample size configurations in a unified workspace, assessing how design choices change expected outcomes and statistical power without having to build bespoke analyses for each question. By anchoring decisions in harmonized data, simulations, and trial precedent rather than manual spreadsheets and ad hoc searches, the platform supports more consistent and transparent rationale behind protocol and operational decisions.

For clinicians, researchers, and trial operations teams, the impact is primarily felt in smaller and more efficient randomized controlled trials, faster design cycles, and clearer evidence to support go/no-go and adaptation decisions. Digital twin–based virtual control arms can reduce the size of control groups while maintaining or improving statistical power, which may shorten recruitment timelines and lower operational burden. The ability to run “what-if” simulations on design scenarios and patient subgroups throughout the study provides more granular visibility into likely trajectories and treatment effects, improving decision quality across the clinical development lifecycle.

Last checked on 23 May 2026: Unlearn.AI remains active as an AI-driven digital twin platform for clinical trials, with recent expansions into new disease models and updated evidence and publications.

What is Unlearn.AI?

Unlearn.AI is a clinical trial optimization platform that uses AI-generated digital twins of trial participants to create virtual control arms and run protocol and operational scenario simulations within randomized and non-randomized studies. It is used by pharmaceutical and biotechnology sponsors and their research partners to design and analyze trials in indications such as neurological and other complex diseases. The platform is differentiated by its disease-specific digital twin generators trained on extensive historical patient data, regulatory-aligned methodologies that have received qualification from the European Medicines Agency for use in Phase 2 and 3 trials, and compliance with standards such as GxP, 21 CFR Part 11, and SOC 2 Type 2.

Why Leading Healthcare Teams Trust Unlearn.AI?

• Unlearn.AI has strategic collaborations with multiple global pharmaceutical companies and biotechs, and its platform is described as being used in Phase 2 and Phase 3 clinical development programs.

• The company reports total funding of more than $130 million, including a $50 million Series C round completed in 2024, which supports its long‑term commercial and R&D roadmap.

• Unlearn.AI’s methodology for using AI-generated digital twins in randomized controlled trials has received a positive qualification opinion from the European Medicines Agency (EMA) for use in certain Phase 2 and Phase 3 trials.

• The company states that its approach aligns with current FDA guidance on the use of external and synthetic controls in late‑phase trials, indicating active engagement with major regulators.

• Unlearn.AI describes its platform and operations as compliant with GxP and 21 CFR Part 11 requirements, and indicates that it has achieved SOC 2 Type 2 attestation for its controls around security and data handling.

• Unlearn.AI publishes detailed technical explanations of its digital twin generators and validation processes, including discussions of how models handle missing data and how they are evaluated for bias and accuracy, which supports transparency for buyers.

• The company highlights that its digital twin models are trained on large, de‑identified longitudinal datasets sourced from over one million patients across many indications, with documented harmonization and data governance processes.

• Public communications emphasize data privacy and protection, including a dedicated privacy policy and explanations of de‑identification and governance practices for clinical data used in model training.

• There are no public reports of mergers, acquisitions, or rebrands affecting Unlearn.AI’s ownership; it continues to operate under the same name as an independent AI company.